Biomarker Technologies Releases Guide to Choosing Spatial Transcriptomics Platforms

Biomarker Technologies (BMKGene) has released a guide aimed at researchers navigating the selection of a spatial transcriptomics platform. The publication emphasizes that the choice of technology should be driven primarily by the biological objectives of the research, rather than solely by the latest technological features.

The guide highlights that different research areas, such as cancer studies or broad brain profiling, have distinct requirements for resolution, sensitivity, and the ability to process various tissue types, including archived FFPE samples. Factors including spatial resolution, gene sensitivity, coverage, assay time, and sequencing and bioinformatics demands are presented as critical considerations.

BMKGene notes that several companies, including 10x Genomics, Vizgen, Resolve Biosciences, and Bruker Spatial Biology, offer varying balances of these capabilities. Some platforms are designed for identifying individual transcripts, while others are better suited for faster profiling of larger regions. The publication also stresses the necessity of evaluating costs, such as reagents, instrument access, and training, particularly when considering scalability.

The guide recommends conducting pilot experiments with representative tissue samples and utilizing multiple biological replicates. It also underscores the importance of verifying expected gene localizations within the correct anatomical context, as well as tracking failure rates and the effort required for data analysis. Careful alignment of platform capabilities, laboratory experience, and research goals is presented as key to achieving meaningful results.